Improvement of Hyperglycemia/Diabetes in Patients to Improve Safety

The goal of this project is to bring together staff and clinicians from Northwestern University/Northwestern Medical Group/Northwestern Memorial Hospital as well as patients and caregivers to assess and redesign the identification and management of hyperglycemia and diabetes during and in transitions of care. There will be 3 different groups for the study: a group of providers [Group 1], a group of patients/caregivers and laypersons [Group 2], and a stakeholder group [Group 3]. Participants will be asked to provide input on potential interventions for a future clinical trial.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2
• Intervention / Treatment: Other: Interviews

• Study Type: Observational
• Enrollment (Actual): 35

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Provider Group: A clinical multidisciplinary team including inpatient endocrine nurse practitioners, nurse coordinators, diabetes educators, outpatient nurses, attending physicians, and pharmacists.

Patient, Caregiver and Layperson Group: The patients who have diabetes/hyperglycemia seen by the Glucose Management Service, the diabetes educator, or the endocrinology service. Caregivers will only be identified by patients if there was a member of their family who helped them with their diabetes management. Laypersons will be identified by research staff as members of the community that can directly advance research and solution development in the field.

Stakeholder Group: Any and all stakeholders that are currently involved in the specific care delivery of diabetes.

Description

Inclusion Criteria:

• Provider Group: Multidisciplinary clinical team (including but not limited to inpatient endocrine nurse practitioners, nurse coordinators, diabetes educators, outpatient nurses, attending physicians, and pharmacists)
• Patient, Caregiver and Layperson Group: Patients must have had hyperglycemia or diabetes at Northwestern Memorial Hospital in the last 5 years.
• Stakeholder Group: Involved in the specific care delivery of diabetes

Exclusion Criteria:

• Provider Group: None
• Patient, Caregiver, and Layperson Group: Patients will be excluded if they did not have diabetes or had hyperglycemia.
• Stakeholder Group: None

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Qualitative Results from Interviews	Participants will be asked to provide their thoughts on potential interventions for a future clinical trial.	Up to one year

Collaborators and Investigators

• Sponsor: Northwestern University

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2022
• Primary Completion (Actual): August 7, 2024
• Study Completion (Actual): December 1, 2025

Study Registration Dates

• First Submitted: October 16, 2023
• First Submitted That Met QC Criteria: October 19, 2023
• First Posted (Actual): October 23, 2023

Study Record Updates

• Last Update Posted (Actual): June 25, 2026
• Last Update Submitted That Met QC Criteria: June 23, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 2; Health Care Quality, Access, and Evaluation; Investigative Techniques; Epidemiologic Methods; Data Collection; Health Care Evaluation Mechanisms; Quality of Health Care; Public Health; Environment and Public Health; Interviews as Topic
• Other Study ID Numbers: STU00090319

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No